Keith Wheatley
Overview
Explore the profile of Keith Wheatley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
143
Citations
6613
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Chisholm J, Mandeville H, Adams M, Minard-Collin V, Rogers T, Kelsey A, et al.
Cancers (Basel)
. 2024 Oct;
16(19).
PMID: 39410054
The authors wish to make corrections to the authorship and title of [...].
2.
OKeeffe H, Green D, de Bhailis A, Chinnadurai R, Wheatley K, Moss J, et al.
Circ Cardiovasc Interv
. 2024 Aug;
17(9):e013979.
PMID: 39145377
Background: The ASTRAL trial (Angioplasty and Stenting for Renal Artery Lesions) recruited 806 patients between 2000 and 2007. Patients with atherosclerotic renal artery stenosis (RAS) and clinician uncertainty about the...
3.
Chaganti S, Maycock S, McIlroy G, Jackson A, Bishop R, Johnson S, et al.
Blood
. 2024 Apr;
144(4):392-401.
PMID: 38643491
Posttransplant lymphoproliferative disorder (PTLD) is a rare complication of solid organ transplantation, and cytotoxic chemotherapy is associated with treatment-related morbidity and mortality. Current treatment takes a sequential, risk-stratified approach, and...
4.
Bailey S, Andre N, Gandola L, Massimino M, Wheatley K, Gates S, et al.
Cancers (Basel)
. 2024 Mar;
16(6).
PMID: 38539574
In the original publication [...].
5.
Chisholm J, Mandeville H, Adams M, Minard-Collin V, Rogers T, Kelsey A, et al.
Cancers (Basel)
. 2024 Mar;
16(5).
PMID: 38473359
The Frontline and Relapsed Rhabdomyosarcoma (FaR-RMS) clinical trial is an overarching, multinational study for children and adults with rhabdomyosarcoma (RMS). The trial, developed by the European Soft Tissue Sarcoma Study...
6.
Wilson J, Main C, Thorp N, Taylor R, Majothi S, Kearns P, et al.
J Neurooncol
. 2024 Mar;
167(1):35-37.
PMID: 38441841
No abstract available.
7.
Fenwick N, Weston R, Wheatley K, Hodgson J, Marshall L, Elliott M, et al.
Front Oncol
. 2024 Feb;
14:1296576.
PMID: 38357205
Background: The survival for many children with relapsed/refractory cancers remains poor despite advances in therapies. Arginine metabolism plays a key role in the pathophysiology of a number of pediatric cancers....
8.
Wilson J, Main C, Thorp N, Taylor R, Majothi S, Kearns P, et al.
J Neurooncol
. 2024 Jan;
167(1):1-34.
PMID: 38294638
Background: Central nervous system (CNS) tumours account for around 25% of childhood neoplasms. With multi-modal therapy, 5-year survival is at around 75% in the UK. Conventional photon radiotherapy has made...
9.
Moreno L, Weston R, Owens C, Valteau-Couanet D, Gambart M, Castel V, et al.
J Clin Oncol
. 2024 Jan;
42(10):1135-1145.
PMID: 38190578
Purpose: Outcomes for children with relapsed and refractory high-risk neuroblastoma (RR-HRNB) remain dismal. The BEACON Neuroblastoma trial (EudraCT 2012-000072-42) evaluated three backbone chemotherapy regimens and the addition of the antiangiogenic...
10.
Alexander S, Auperin A, Bomken S, Csoka M, Kazanowska B, Chiang A, et al.
Lancet Haematol
. 2023 Apr;
10(6):e445-e457.
PMID: 37094596
Background: Survival of children and adolescents with high-risk, mature B-cell non-Hodgkin lymphoma is improved by the addition of rituximab to chemotherapy. The effect of rituximab on immune reconstitution after therapy...